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Abstract
Nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) are
among the most widely used classes of medications to treat pain
and inflammation. However, gastrointestinal complications
associated with NSAIDs are prevalent, largely due to the frequent
use of these agents. Adverse events associated with NSAIDs
include minor side effects, such as dyspepsia, as well as serious
complications, such as bleeding and perforation. Although the
probability that any given individual user of an NSAID will suffer a
serious gastrointestinal complication is fairly low, widespread
patient exposure can translate into a major national health burden.
The increasing use of aspirin in the prevention of cardiovascular
events and the availability of select over-the-counter NSAIDs
represent additional challenges to clinicians in their efforts to make
the most appropriate therapeutic decisions while minimizing the
potential gastrointestinal risks associated with the use of these
agents. Side effects such as dyspepsia do not provide adequate
warning of gastrointestinal complications, because most
complications occur without the presence of antecedent
symptoms. Therefore, accurate risk assessment and the manage-
ment of controllable risk factors are crucial to the safe administra-
tion of NSAIDs. This review focuses on the gastrointestinal effects
of aspirin, acetaminophen, and other nonselective NSAIDs, and
discusses those factors that are associated with increased risk for
adverse gastrointestinal events in certain individuals.
Introduction
Gastrointestinal complications are strongly associated with
the use of conventional nonsteroidal anti-inflammatory drugs
(NSAIDs) and are recognized as the most prevalent and
severe cause of drug toxicity in the USA [1]. Millions of
patients use NSAIDs for the relief of various types of arthritis
pain, stiffness, and related symptoms. Selective NSAIDs such
as cyclo-oxygenase (COX)-2 inhibitors were first introduced
with the purpose of providing symptomatic pain relief along
with lesser gastrointestinal risk. Recent studies indicated that
COX-2 inhibitors were prescribed more often than NSAIDs in
patients who are older, sicker, and have risk factors
associated with NSAID gastropathy [2].
However, rofecoxib (Vioxx®; Merck & Co., Inc., Whitehouse
Station, NJ, USA) was voluntarily withdrawn in September
2004; valdecoxib (Bextra®; Pfizer, Inc., New York, NY, USA)
was withdrawn and a ‘black box’ warning was added for
celecoxib (Celebrex®; Pfizer, Inc., New York, NY, USA) in
April 2005; and a joint hearing of the US Food and Drug
Administration Arthritis Committee and the Drug Safety and
Risk Management Committee found that the use of COX-2
inhibitors is associated with increased risk for cardiovascular
events [3]. These recent events have led many physicians to
consider the use of traditional NSAIDs in combination with a
proton pump inhibitor (PPI) to reduce the gastrointestinal
side effects of NSAIDs. Indeed, major treatment guidelines
recommend PPI prophylaxis in patients with a previous
gastrointestinal event and in those at high risk for
complications [4].
NSAID-induced gastrointestinal complaints are among the
most commonly reported adverse events. Balancing these
benefits and risks is an important clinical goal in the post-
Vioxx and post-Bextra era. Reducing the risk for gastro-
intestinal complications requires a thorough understanding
of potential complications and underlying predisposing risk
factors, which is a particularly important consideration in
light of the fact that many individuals develop
complications without antecedent warning signs or
symptoms. This review provides updated information on
traditional NSAIDs, including details regarding their
efficacy and safety, and a discussion of the major risk
factors that are commonly associated with gastrointestinal
complications.
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Spectrum of gastrointestinal risk
The association between NSAIDs and gastrointestinal
erosions and ulcers is well established. The relative risk for
experiencing serious adverse gastrointestinal events is
approximately three times greater for NSAID users than for
nonusers [5]. Furthermore, patients with rheumatoid arthritis
(RA) are nearly twice as likely as those with osteoarthritis (OA)
to suffer a serious complication from NSAID treatment [6].
Compared with RA, OA is a milder disease and requires lower
doses of NSAIDs, which may explain why patients with OA
appear to be at lower risk for gastrointestinal complications.
NSAID gastrointestinal damage is mediated through several
mechanisms that compromise mucosal integrity. In addition,
NSAIDs, particularly aspirin, inhibit platelet function even at
low dosage, giving rise to bleeding that most commonly
affects the gastrointestinal tract. The distinction between
erosions and ulcers depends on pathological and endoscopic
definitions, with ulcers defined as lesions that penetrate to the
level of the submucosa (involving endoscopically evident
depth) and erosions defined as lesions confined to the
mucosa (without endoscopically appreciable depth). Ulcers
give rise to major bleeding, perforation, or obstruction.
NSAID-related gastrointestinal adverse events can be classified
into three broad categories [7]: ‘nuisance’ symptoms such as
heartburn, nausea, dyspepsia, and abdominal pain; mucosal
lesions (which may or may not be symptomatic), such as
ulcers; and serious gastrointestinal complications, such as
perforated ulcers and catastrophic bleeding. Nuisance or minor
gastrointestinal side effects, including nausea, dyspepsia,
anorexia, abdominal pain, flatulence, and diarrhea, are common
and affect between 10% and 60% of NSAID users. Mucosal
lesions are also common, with nearly half of all patients who
take NSAIDs on a regular basis having gastric erosions and
15–30% having endoscopically detectable ulcers. The majority
of these lesions do not cause significant symptoms [8,9].
Clinically significant upper gastrointestinal events occur in
3–4.5% of NSAID users annually. The majority of these events
are symptomatic ulcers whereas a smaller percentage
(approximately 1%) are clinically serious and associated with
gastrointestinal bleeding, perforation, or obstruction [10,11].
Throughout the 1980s, the overall risk for hospitalization
resulting from gastrointestinal complications was estimated at
approximately 1% per year in persons taking NSAIDs [1].
Recent data indicate that the incidence has declined
substantially, to 0.5%, as a result of a number of factors,
including lower doses of NSAIDs, use of gastroprotective
agents (PPIs and misoprostol), and the introduction of the
selective COX-2 inhibitors [12]. However, patients taking
NSAIDs are 6.45 times more likely to be hospitalized for a
gastrointestinal complication than are nonusers [1,6] (Table 1).
The number of deaths associated with NSAID-induced
gastrointestinal damage, as acquired from ARAMIS (the
Arthritis, Rheumatism, and Aging Medical Information
System), which included postmarketing surveillance of more
than 36,000 patients from 17 centers in the USA and
Canada, are staggering and are comparable to mortality
statistics for AIDS and other terminal diseases (Fig. 1) [6,11].
Magnitude of risk for gastrointestinal
complications associated with NSAIDS
Although only a relatively small proportion of NSAID users
actually develop major gastrointestinal complications, the
importance of these complications is magnified by the
widespread use of these agents, thus translating this
proportion into a large absolute number of toxicities. More than
30 million individuals are estimated to take NSAIDs daily [6].
Over 111 million NSAID prescriptions were written in the year
ending in August 2000 [6]. Additionally, more than 30 billion
over-the-counter (OTC) NSAIDs are purchased annually [13].
The prevalence of at least a once weekly NSAID dose among
elderly patients aged 65 years or older has been reported to
be as high as 70% (original source [7]; primary source [14]).
This is particularly significant when it is considered that
increasing age is an independent risk factor for gastro-
intestinal complications.
Several risk factors are known to increase substantially an
individual’s risk for NSAID-induced gastrointestinal events
[7]. These include a history of ulcer, presence of Helicobacter
pylori infection, use of more than one NSAID (including
aspirin), use of high-dose NSAIDs, concurrent anticoagulant
or corticosteroid use, a serious underlying disease, and age
greater than 75 years. The severity of RA may also be directly
related to an increased risk for gastrointestinal events. In
contrast, dyspepsia and other upper gastrointestinal symptoms
do not reliably predict the development of upper gastro-
intestinal events [7].
The role played by H pylori in the development of
gastrointestinal complications remains a subject of
controversy. In a recent meta-analysis of 25 studies [15],
H pylori infection in NSAID users was associated with a 3.53-
fold increased risk for peptic ulcer disease above the risk
associated with NSAID use alone. The use of NSAIDs and
H pylori infection increased the risk for ulcer bleeding 4.85-
fold and 1.79-fold, respectively; the risk for ulcer bleeding
increased to 6.13-fold when both factors were present.
Therefore, although both NSAIDs and H pylori independently
confer increased risk, these findings also a synergistic
interaction between these two factors, which leads to
increased incremental risk.
The highest relative risk for gastrointestinal events is
associated with a history of complicated ulcer or multiple
NSAID use (Table 2) [5,7,16-18]. In one study, in which
1457 patients with a history of bleeding were compared with
10,000 control individuals, patients on multiple NSAIDS9
regimens were nine times more likely to experience upper
gastrointestinal bleeding than were control individuals [19].
The correlation between multiple NSAID use and upper
gastrointestinal bleeding should be placed in a broader
perspective, not only because of the widespread use (and
considerable under-reporting) of OTC medications but also
because patients do not recognize the potential
complications that can develop with NSAIDs. A survey of
more than 800 people found that approximately 65% said
that they suffer gastrointestinal symptoms before the onset of
a gastrointestinal event, despite considerable evidence that
serious gastrointestinal complications occur in asymptomatic
patients [20].
Many patients taking OTC NSAIDs and/or aspirin or other
drugs do so without their physician’s knowledge or approval,
and are unaware of the increased relative risk for
experiencing a gastrointestine related event. This widespread
use of NSAIDs underscores the importance of a thorough
assessment of potential gastrointestinal risk in patients who
are administered these agents for the management of pain
and inflammation. Obtaining accurate information regarding
concomitant medications from patients taking NSAIDs may
also help to identify those at additional risk from concurrent
multiple NSAID, anticoagulant, or corticosteroid use.
Assessment of gastrointestinal risk factors
It is imperative that clinicians carefully screen patients for risk
factors for gastrointestinal complications due to NSAID use.
Although dyspepsia is a frequent side effect of NSAIDs use,
it is not – in contrast to common perception – an accurate
predictor of gastrointestinal complications [6,7]. Approxi-
mately 15% of patients experience dyspepsia during NSAID
therapy, but such symptoms correlate poorly with the severity
of mucosal injury. As many as 50% of patients with dyspepsia
have mucosa that appears normal on endoscopic examina-
tion. In fact, the majority of patients who develop gastro-
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Table 1
Gastrointestinal complications in osteoarthritis versus rheumatoid arthritis
OA hospitalizations RA hospitalizations RA deaths
Number of patients 1283 3883 2921
Person years of observation 3234 19,961 12,224
Person years taking NSAID 2199 15,638 8471
Number of GI events 19 228 25
Number of GI events while taking NSAID 16 205 19
Rates/year (%) while taking NSAID 0.73 1.31 0.22
Rates/year (%) while not taking NSAID 0.29 0.19 0.05
Relative risk while taking NSAID 2.51 6.77 4.21
GI, gastrointestinal; NSAID, nonsteroidal anti-inflammatory drug; OA, osteoarthritis; RA, rheumatoid arthritis. Reproduced with permission from [6].
Figure 1
Deaths associated with NSAID induced gastrointestinal damage
versus other causes. GI, gastrointestinal; NSAID, nonsteroidal anti-
inflammatory drug. Data from Singh and Triadafilopoulos [6].
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Table 2
Risk factors for aspirin and NSAID associated ulcer
complications, in order of relative importance
Rank Risk factor
1 Personal history of complicated ulcer disease
2 Concurrent use of more than one NSAID (including aspirin)
3 Use of high doses of NSAIDs
4 Concurrent use of an anticoagulant
5 Personal history of uncomplicated peptic ulcer disease
6 Age >70 years
7 Concurrent use of steroids
NSAID, nonsteroidal anti-inflammatory drug. Reproduced with
permission from Elsevier [16].S10
intestinal complications do so without any antecedent
symptoms [21], further highlighting the importance of
thorough risk assessment in patients receiving NSAIDs.
Some advocates of H pylori screening recommend that
H pylori eradication be considered in chronic NSAID users at
average risk for gastrointestinal complications, as well as in
chronic NSAID users at increased risk for gastrointestinal
complications [22]. However, patients with gastric and
duodenal ulcers may or may not have evidence of H pylori
infection [23], and H. pylori eradication may reduce but not
completely eliminate the risk for recurrent ulcers or complica-
tions [24]. Therefore, this issue remains controversial.
It should be noted that the period of greatest risk to an
individual taking NSAIDs occurs during the first 3 months of
NSAID therapy. Although the underlying mechanism for this is
not well understood, one theory holds that gastric mucosa
adapts to NSAID use over time [5]. However, clinical findings
from a study in which 1600 individuals receiving NSAID
therapy were followed for up to 15 years [6] demonstrated
that the stomach does not adapt to NSAID use, and that the
risk for complications continues over the long term [6].
Further elucidation of the mechanisms that are involved in
early NSAID associated gastrointestinal events may help to
ascertain which individuals are at greatest risk for early
gastrointestinal events.
Comparison of gastrointestinal effects:
aspirin, acetaminophen, and NSAIDs
The anti-inflammatory, analgesic, and antipyretic drugs are a
heterogeneous group of compounds that share certain
therapeutic actions and side effects, although they are
chemically unrelated. Attempts to rank toxicity and efficacy
have not been consistent. Earlier studies conducted by Henry
and colleagues [25] established a comparative toxicity range
for a select group of drugs (using ibuprofen as the reference
comparator); for example, the relative risk (RR) for aspirin was
found to be 1.6, for diclofenac it was 1.8, for naproxen it was
2.2, and for ketoprofen it was 4.2. A more recent nested case
controlled analysis [26] showed that aspirin was associated
with a RR of 2.9 for uncomplicated peptic ulcer, compared
with a RR of 4.0 for nonaspirin NSAIDs.
Low-dose aspirin and NSAIDs are among the most widely
used drugs worldwide. Because of their anti-inflammatory
and analgesic (NSAIDs) or antiplatelet (low-dose aspirin)
effects, these drugs can benefit patients substantially but at
the cost of increased risk for gastrointestinal complications.
The benefits of low-dose aspirin in the prevention of myo-
cardial infarction and vascular events are well established
[27]. The American Heart Association recommends the use
of low-dose aspirin (75–160 mg) in patients whose 10-year
risk for a cardiovascular event is 10% or greater, except in
persons at high risk for gastrointestinal bleeding or
hemorrhagic stroke [28]. Long-term use of aspirin in the
prevention of cardiac disease, especially in elderly
populations, is of increasing concern because it is wide-
spread and is known to cause irritation and injury to the
gastrointestinal tract [29].
Recent clinical findings suggest that no aspirin regimen is
free from risk for upper gastrointestinal bleeding [30]. Even
lose-dose aspirin is associated with a significant increase in
upper gastrointestinal bleeding. In a Danish registry of
27,694 users of low-dose aspirin (100–150 mg) the
incidence of upper gastrointestinal bleeding upon admission
to the hospital was 2.6-fold greater than in the general
population [30]. The risk for upper gastrointestinal bleeding
(incidence ratio 5.6) is even greater among patients taking
other NSAIDs in combination with aspirin and is not dose
dependent [30,31].
In contrast to aspirin, the use of low-dose acetaminophen
(<2000 mg) is not associated with an increased risk for
upper gastrointestinal complications. There are limited data
that suggest that doses greater than 2 g are associated with
an increased risk for gastrointestinal bleed or perforation by a
factor of 3.6 [32]. In vitro analyses of human whole blood
assays suggest that acetaminophen is a weak nonselective
inhibitor of both COX-1 and COX-2 [33].
Currently, the American College of Rheumatology (ACR)
recommends acetaminophen as first-line treatment for OA of
the knee or hip. This is largely because of the perception that
acetaminophen is safer than NSAIDs [34,35]. However, the
selection of treatment depends on a balance of factors,
including efficacy, safety, tolerability, availability, cost, and
patient acceptance. The recent emergence of coxibs has
raised further questions regarding the role of selective
NSAIDs in the treatment of OA. Until recently, few
comparison data were available with which to evaluate the
relative efficacy and safety of acetaminophen and NSAIDs.
Data from clinical trials demonstrated that celecoxib and
diclofenac are both superior to acetaminophen in the
treatment of OA [36,37]. Furthermore, a survey of 1799
patients found that the majority of patients with OA (>60%)
prefer NSAIDs to acetaminophen in the symptomatic
treatment of the condition based on perceived better efficacy
[38]. However, newer data from several meta-analyses and
pooled analyses evaluating the comparative efficacy and
safety of NSAIDs versus acetaminophen indicate that,
although NSAIDs are slightly more effective in relieving pain,
acetaminophen is associated with fewer adverse reactions
and less frequent gastrointestinal discomfort than are
NSAIDs.
In a meta-analysis of seven clinical trials performed by Lee
and colleagues [39], the efficacy and safety of NSAIDs,
including coxibs, in the treatment of symptomatic hip and
knee OA were compared with those of acetaminophen. Lee
and coworkers determined that NSAIDs are statistically
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superior to acetaminophen in reducing walking and rest pain;
however, NSAIDs were also associated with an elevated, but
statistically insignificant, risk for withdrawals due to adverse
events (odds ratio 1.45, 95% confidence interval [CI]
0.93–2.27).
Based on the results from another meta-analysis of 10
randomized controlled trials (n = 1712), in which patients
with symptomatic OA of the knee, hip and knee, or multiple
joints were evaluated, Zhang and colleagues [40] reported
that acetaminophen was significantly more effective than
placebo (effect size 0.21, 95% CI 0.02–0.41) but that
NSAIDs were better than acetaminophen for pain relief
(effect size 0.20, 95% CI 0.10–0.30), clinical response rate
(RR 1.24, 95% CI 1.08–1.41), and symptom relief (as
measured using Western Ontario and McMaster Universities
Osteoarthritis Index scores). The number of patients who
preferred NSAIDs was more than twice the number of patients
who preferred acetaminophen (RR 2.46, 95% CI 1.51–4.12).
Although NSAIDs exhibited superior efficacy in the meta-
analysis conducted by Zhang and coworkers [40], the
excellent safety profile of acetaminophen must be weighed
against the therapeutic benefits of NSAIDs. In this meta-
analysis, NSAIDs were associated with more frequent gastro-
intestinal discomfort, including abdominal pain, gastro-
intestinal distress, nausea, vomiting, and dyspepsia, than was
acetaminophen (RR 1.35, 95% CI 1.05–1.75). It should be
noted, however, that the studies examined in this meta-
analysis included only short-term trials in which serious gastro-
intestinal events, such as bleeding or ulcer complications,
were not evaluated. In balancing the efficacy and safety data
for acetaminophen and NSAIDs, Zhang and colleagues
concluded that acetaminophen at 4 g/day demonstrates
significant efficacy for pain relief in OA, and that the current
ACR guidelines that recommend acetaminophen as first-line
treatment for OA are supported by the evidence. Overall,
however, acetaminophen is not adequate therapy for the
majority of patients with daily OA pain.
Acetaminophen is generally thought to be safer than
NSAIDs, although the therapeutic index is narrow and a
single acetaminophen overdose with twice the highest
labeled dose is associated with life-threatening acute liver
failure [41,42]. There have been few case reports of
acetaminophen-induced acute liver failure at therapeutic
doses [43]. In a prospective study of acute liver failure at 17
tertiary care centers in the USA [44], involving 308 patients
with liver failure over the course of more than 3 years, liver
failure due to acetaminophen overdose accounted for 39% of
all cases. Comparatively, viral hepatitis (A and B), a common
cause of liver failure, accounted for only 12% of cases.
Although acetaminophen overdose has replaced viral
hepatitis as the most frequent putative cause of acute liver
failure, it remains extremely rare given the ubiquitous use of
this OTC analgesic.
The evidence for decreased gastrointestinal risk in patients
receiving COX-2 is reviewed extensively elsewhere. However,
the data presented here provide a context for discussion of
the benefits and risks of these agents. Endoscopic studies,
meta-analyses of serious gastrointestinal adverse events from
clinical trials, and outcome studies have demonstrated the
improved gastrointestinal safety of coxibs compared with
most NSAIDs studied. Concerns over cardiovascular risk,
however, have cast a shadow over the perceived overall
safety profile of chronic coxib therapy. In addition, in patients
with RA who are at risk for serious adverse gastrointestinal
complications, the ACR recommends the use of one of the
following [18]: low-dose prednisone instead of an NSAID; a
nonacetylated salicylate; a highly selective COX-2 inhibitor;
or a combination of NSAID and a gastroprotective agent. A
safety issue related to NSAID and coxib safety that is not fully
addressed in such guidelines, which are now 3 years old, is
that low-dose aspirin (75–300 mg/day) for the prevention of
stroke and myocardial infarction is increasingly common,
especially in older patients. Because the concurrent use of
aspirin with NSAIDs is common, the potential impact on
safety should be weighed in patients receiving both selective
and nonselective NSAIDs. Data available to date suggest that
the potential gastrointestinal safety benefit of coxibs
compared with NSAIDs is lost with aspirin cotherapy.
Cardiovascular risk
Before the development of COX-2 inhibitors, the risks
associated with NSAIDs precluded robust study of such
agents for various preventive indications. These indications
have included prevention of cancer, Parkinson’s disease and
Alzheimer’s dementia. The perceived safety of patented COX-2
selective inhibitors generated the financial and ethical support
for long-term exposure in a setting in which it was ethical to
conduct a comparison with placebo. Previously, only sympto-
matic conditions were studied, and so long-term placebo
control was not possible. Results of placebo controlled, long-
term clinical trials with over 2 years of exposure have indicated
that there is cardiovascular risk associated with rofecoxib.
Similar trials using celecoxib have been less consistent.
Somewhat unexpectedly, the single long-term, placebo
controlled study of a nonselective NSAID, namely naproxen,
has been preliminarily reported as suggesting that there is
cardiovascular risk with this agent, although a final report is
not yet available. There have been at least seven large
pharmacoepidemiologic studies on this topic published since
2001, with over 5 million person years of exposure. However,
it is not clear whether all COX-2 selective agents entail
cardiovascular risk, whether nonselective agents entail risk, or
what effect dose and duration have on magnitude of risk [45].
The Food and Drug Administration has requested that all
NSAID and COX-2 selective agents carry warnings that the
product may increase the risk for cardiovascular events [46].
(This issue is addressed in greater detail elsewhere in this
supplement [3,47].)
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Thus, it is important to reassess the ACR recommendations
in the light of newer safety information. Co-use of NSAIDs
and gastroprotective agents appears to be more attractive.
Gastroprotective agents, which are considered to be
effective in decreasing NSAID-associated gastrointestinal
ulceration, include high-dose H2 blockers, PPIs, and the oral
prostaglandin analog misoprostol. Although symptoms of
dyspepsia often improve in patients treated with H2 blockers,
their routine use is not recommended because of findings in
1921 patients from the ARAMIS cohort that prophylactic
treatment with these agents may increase the risk for
subsequent serious gastrointestinal complications [21].
Numerous studies indicated that, when used in conjunction
with NSAIDs, PPIs and the oral prostaglandin analog
misoprostol significantly reduce gastric and duodenal ulcers
in patients with and without a prior history of ulcers [8,48-52].
A recent study conducted by Chan and coworkers [53]
raises the question regarding whether such a strategy is
adequate in those who are at particularly high risk, based on
a past history of upper gastrointestinal bleed. Despite these
recent conflicting findings, the protective effects of these
agents are well established (their efficacy is further evaluated
in another review in this supplement [54]).
Conclusion
Thorough risk assessment and prevention strategies together
offer the best opportunity to prevent harmful gastrointestinal
events in patients receiving NSAIDs. When selecting
therapeutic agents, physicians should consider recent
findings that further characterize the comparative safety and
efficacy profiles of acetaminophen and NSAIDs, and should
discuss with patients the potential benefits and risks of
various treatments. Tailoring the options outlined in this article
to a particular patient is the challenge for those caring for
patients with OA. Future studies may help to quantify better
the benefit of PPI cotherapy for chronic NSAID users
compared with acetaminophen or COX-2 selective agents.
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